2026-04-13T02:22:33Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/91732025-10-24T10:43:14Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Peg Camara, Vicente
author
Reverté Calvet, Laia
author
Bosch Príncep, Ramon
author
Lejeune, Marylène
author
Sauras-Colón, Esther
author
Gallardo Borràs, Noèlia
author
Roso-Llorach, Albert
2025-10-24T10:43:14Z
2025-10-24T10:43:14Z
2023-03-15T09:12:02Z2023-03-15T09:12:02Z2023-01-18
http://hdl.handle.net/11351/9173
Neoadjuvant therapy; Relapse; Triple-negative breast cancerTerapia neoadyuvante; Recaída; Cáncer de mama triple negativoTeràpia neoadjuvant; Recaiguda; Càncer de mama triple negatiuWith a high risk of relapse and death, and a poor or absent response to therapeutics, the triple-negative breast cancer (TNBC) subtype is particularly challenging, especially in patients who cannot achieve a pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). Although the tumor microenvironment (TME) is known to influence disease progression and the effectiveness of therapeutics, its predictive and prognostic potential remains uncertain. This work aimed to define the residual TME profile after NAC of a retrospective cohort with 96 TNBC patients by immunohistochemical staining (cell markers) and chromogenic in situ hybridization (genetic markers). Kaplan–Meier curves were used to estimate the influence of the selected TME markers on five-year overall survival (OS) and relapse-free survival (RFS) probabilities. The risks of each variable being associated with relapse and death were determined through univariate and multivariate Cox analyses. We describe a unique tumor-infiltrating immune profile with high levels of lymphocytes (CD4, FOXP3) and dendritic cells (CD21, CD1a and CD83) that are valuable prognostic factors in post-NAC TNBC patients. Our study also demonstrates the value of considering not only cellular but also genetic TME markers such as MUC-1 and CXCL13 in routine clinical diagnosis to refine prognosis modelling.This research was supported by grants from the Instituto de Salud Carlos III (PI13/02501 and PI11/0488) co-financed by the European Regional Development Fund (ERDF). ML acknowledges support from the “PATH-IMAGE” project, which was funded by ERDF (agreement 2903/335-41).
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Mama - Càncer - Quimioteràpia
Mama - Càncer - Prognosi
Resistència als medicaments
Marcadors genètics
PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Microenvironment::Tumor Microenvironment
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Combined Modality Therapy::Neoadjuvant Therapy
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Genetic Markers
FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::microambiente celular::microambiente tumoral
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento combinado::tratamiento neoadyuvante
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores genéticos
Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion